(Q36203263)

12 August 2017

1 reference

title

Rational use of oral bisphosphonates for the treatment of osteoporosis (English)

1 reference

12 August 2017

0 references

Julian M R Mathoo

1

1 reference

12 August 2017

Ann Cranney

series ordinal

2

1 reference

12 August 2017

Alexandra Papaioannou

series ordinal

3

1 reference

12 August 2017

Jonathan D Adachi

series ordinal

4

1 reference

12 August 2017

language of work or name

1 reference

1 March 2004

1 reference

Current osteoporosis reports

12 August 2017

published in

1 reference

12 August 2017

volume

2

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

17-23

1 reference

Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force

12 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11914-004-0010-6

Clinical use of bone densitometry: clinical applications.

21 January 2018

1 reference

12 December 2020

Bisphosphonates: mechanisms of action

1 reference

12 December 2020

Modelling in economic evaluation: an unavoidable fact of life

1 reference

12 December 2020

The cost utility of bisphosphonate treatment in established osteoporosis

1 reference

12 December 2020

The pharmacology and therapeutic utility of bisphosphonates

1 reference

12 December 2020

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

1 reference

12 December 2020

Bone densitometry: the best way to detect osteoporosis and to monitor therapy

1 reference

12 December 2020

Treatment of established osteoporosis: a systematic review and cost-utility analysis.

1 reference

12 December 2020

Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study

1 reference

12 December 2020

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

12 December 2020

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

1 reference

12 December 2020

An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae

1 reference

12 December 2020

Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review

1 reference

12 December 2020

Alendronate for the Treatment of Osteoporosis in Men

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis

1 reference

12 December 2020

Use of cyclical etidronate and prevention of non-vertebral fractures.

1 reference

12 December 2020

Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures

1 reference

12 December 2020

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Mortality following fractures in older women. The study of osteoporotic fractures

1 reference

12 December 2020

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group

1 reference

12 December 2020

A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 1. Introduction

1 reference

12 December 2020

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

1 reference

12 December 2020

Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group

1 reference

12 December 2020

Biomechanics of bone: determinants of skeletal fragility and bone quality

1 reference

12 December 2020

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

12 December 2020

2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.

1 reference

12 December 2020

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

12 December 2020

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

12 December 2020

Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials

1 reference

12 December 2020

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

1 reference

12 December 2020

Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures

1 reference

12 December 2020

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

10.1007/S11914-004-0010-6

Identifiers

DOI

1 reference

12 August 2017

1 reference